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state in human subjects and particularly 
with an increase in inflammatory markers 
(Ruggiero et al., 2006).
URIC ACID METABOLISM AND ATRIAL 
REMODELING
Potential sources and factors implicated in 
AF-related oxidative stress include NADPH 
oxidase activation, calcium overloading and 
mitochondrial damage, angiotensin system 
activation, NO synthase uncoupling, XO 
activation, altered expression of redox-
related genes, other genetic factors, aging, 
obesity, and other associated cardiovascular 
conditions (Korantzopoulos et al., 2007). 
The presence and localization of XO in 
the human heart has been debated. Earlier 
studies found no evidence of XO activity 
(Grum et al., 1989) while latter studies 
confirmed the presence of XO activity in 
human hearts (MacGowan et al., 1995) 
and besides its localization in capillary 
endothelial cells additional localization in 
vascular smooth muscle cells, macrophages, 
and mast cells was demonstrated (Hellsten-
Westing, 1993).
In a porcine atrial tachypacing model 
of AF left atrial XO activity was 4.4 times 
greater in the paced than in the control 
group. Superoxide production was reduced 
by 85% after administration of oxypurinol 
(a XO inhibitor; (Dudley et al., 2005). In this 
model, XO in the atria was less abundant 
than NADPH oxidase. It is worth noting 
that in another study no significant effect 
of oxypurinol on superoxide production 
was found in human atrial specimens, thus 
failing to support a role of XO in oxida-
tive stress associated with human AF (Kim 
et al., 2005). A potential explanation for this 
evident discrepancy could be the existence 
of regional differences since in the porcine 
model the increased XO activity was appar-
ent in the left atrial appendage (Dudley 
et al., 2005), whereas in the human study 
only tissue specimens from right atrial 
appendage were examined (Kim et al., 
2005). Of note, in a similar porcine model, 
forming the toxic molecule peroxynitrite. 
Collectively, ROS such as hydroxyl radicals 
and peroxynitrite trigger cellular responses 
ranging from subtle changes of cell func-
tioning to severe oxidative damage of the 
affected macromolecules leading to necrosis 
or apoptosis (Glantzounis et al., 2005).
The highest activity of XO is detected 
in endothelium, intestine, and liver. 
Endothelial XO plays a crucial role in the 
vascular oxidative stress. Remarkably, 
angiotensin II-induced NADPH oxidase 
activation increases XO activity indicating 
that there is a redox sensitive activation of 
endothelial XO (Landmesser et al., 2007). 
It has also been suggested that endothelial-
derived ROS have direct effects on myocar-
dial functional performance (Doehner and 
Landmesser, 2011).
UA has emerged as a simple and inde-
pendent marker of morbidity and mortality 
in a variety of cardiovascular disease states 
including coronary artery disease and heart 
failure (Dawson and Walters, 2006; George 
and Struthers, 2008; Ndrepepa et al., 2012). 
Regardless of the debate whether it is a pre-
dictor or a causative factor, UA has been 
clearly associated with oxidative stress and 
inflammation in several pathological con-
ditions (Glantzounis et al., 2005; Doehner 
and Landmesser, 2011). It has also been pro-
posed that UA reflects the presence of other 
diseases and cardiovascular risk factors that 
increase oxidative stress.
In pathophysiological terms, UA reflects 
upregulated XO activity. Apart from this 
well-known pathway, UA may have addi-
tional effects. Specifically, it appears to be 
a low potency antioxidant outside the cell 
(Glantzounis et al., 2005). On the other 
hand, inside the cell it enhances oxida-
tive stress by activating NADPH oxidase 
while it activates the renin-angiotensin 
system (Kelkar et al., 2011). Moreover, UA 
may represent an endogenous signal of 
cell injury activating the cellular immune 
response (Shi et al., 2003). In fact, UA has 
been associated with a pro-inflammatory 
BACKGROUND
The pathophysiology of atrial remodeling is 
very complex and the molecular pathways 
implicated in the initiation and perpetua-
tion of atrial fibrillation (AF) show a high 
diversity and variability across different 
underlying substrates (Schotten et al., 2011; 
Wakili et al., 2011). During the past few 
years the role of pathophysiologic pathways 
that involve inflammatory and oxidative 
processes is under meticulous investigation 
(Korantzopoulos et al., 2007; Van Wagoner, 
2008; Negi et al., 2010). Given that most of 
the published data on this subject regards 
the study of inflammatory and oxidative 
stress markers, the cause-effect relation-
ship with atrial remodeling is not very clear. 
Possibly, both procedures are operative in 
this setting. Bearing in mind that most of 
the associated cardiovascular conditions 
are associated with oxidative stress and 
inflammation, the study of oxidative, and 
inflammatory aspects of atrial remodeling 
becomes more complicated.
XANTHINE OXIDASE AND URIC ACID IN 
CARDIOVASCULAR DISEASE
Accumulating evidence suggests that xan-
thine oxidase (XO) is an important source 
of reactive oxygen species (ROS) in cardio-
vascular disease (Doehner and Landmesser, 
2011). In specific, uric acid (UA) derives 
from the conversion of hypoxanthine 
to xanthine and of xanthine to UA, both 
reactions being catalyzed by the enzyme 
XO (Glantzounis et al., 2005). Ischemia 
and cellular damage promote xanthine 
accumulation creating a substrate for XO. 
This enzyme uses molecular oxygen as elec-
tron acceptor and leads to formation of 
the free radical superoxide anion, thereby 
promoting oxidative stress (Glantzounis 
et al., 2005). Superoxide anion can form 
hydrogen peroxide through superoxide 
dismutase activity and, in the presence of 
iron, the extremely reactive hydroxyl radi-
cal by Fenton-type reactions. Also, superox-
ide anion interacts with nitric oxide (NO) 
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has been shown that statins, agents with 
antioxidant properties that may favorably 
affect atrial remodeling, decrease UA levels, 
at least in part, by increasing its fractional 
excretion (Moutzouri et al., 2012).
Allopurinol represents a competi-
tive inhibitor of XO at low doses and a 
non-competitive inhibitor at high doses 
which is in clinical use for the treatment 
of hyperuricemia (Kelkar et al., 2011). It 
has been shown that allopurinol improves 
endothelial dysfunction in a variety of 
clinical conditions (Kelkar et al., 2011). 
Notably, recent clinical evidence suggests 
that allopurinol reduces blood pressure in 
essential hypertension (Feig et al., 2008), 
and exerts significant anti-ischemic effects 
in patients with stable angina (Noman 
et al., 2010). It should be pointed out 
that, in contrast to older studies, high-
dose allopurinol schemes were tested in 
these studies. In keeping with these find-
ings, a large cohort study indicated that 
high-dose allopurinol use (≥300 mg/day) 
is associated with a lower-risk for cardio-
vascular events and all-cause mortality 
compared to lower doses (Wei et al., 2011). 
No clinical trial to date has examined the 
effect of allopurinol administration on 
AF. Only one observational study, pub-
lished in the abstract form, reported that 
patients receiving UA lowering agents had 
decreased AF prevalence without men-
tioning further details (Kuwabara et al., 
2012). Furthermore, it has been reported 
that high-dose allopurinol may reduce the 
incidence of complications after coronary 
bypass surgery, including arrhythmias 
(Weimert et al., 2003).
Interestingly, in a very recent experi-
mental study using a dog model of atrial 
tachypacing – induced cardiomyopathy, 
allopurinol attenuated the reduction of 
atrial effective refractory period and the 
duration of AF while suppressed the atrial 
fibrosis and the reduction endothelial NO 
synthase protein expression without affect-
ing the left ventricular ejection fraction 
or the LA diameter (Sakabe et al., 2012). 
Apart from potential direct effects on atrial 
remodeling, the aforementioned favorable 
hemodynamic effects of high-dose allopu-
rinol may provide additional benefit in AF. 
Finally, there are no data on the cardio-
vascular effects of the newly released non-
purine XO inhibitor febuxostat.
AF in hypertensive patients without sig-
nificant comorbidities (Liu et al., 2011). In 
the ARIC study, a large prospective cohort 
study, elevated serum UA was associated 
with a greater risk of AF development dur-
ing the follow-up (Tamariz et al., 2011). 
Particularly, this association was evident 
only among blacks and among women 
(Tamariz et al., 2011). In the same line, a 
Japanese hospital-based cohort study indi-
cated an independent association between 
serum UA and AF in women but not in men 
(Suzuki et al., 2012). We have also shown 
that UA is an independent predictor of AF 
recurrence after AF ablation (Letsas et al., 
2011). Another very recent study showed 
that UA levels ≥8 mg/dl was an independ-
ent predictor of AF while UA increased 
significantly between the last year and the 
year of the first AF detection suggesting a 
possible involvement in AF development 
(Kuwabara et al., 2012). Collectively, the 
aforementioned studies indicate that UA 
represents a marker of AF development 
and perpetuation but the cause-effect rela-
tionship is not clear (Watanabe, 2012). Also, 
the mechanisms underlying race and gender 
differences have not been elucidated yet.
Of note, hyperuricemia is associated 
with increased incidence of stroke as well 
as increased stroke-related mortality (Kim 
et al., 2009). In addition, it has been shown 
that high serum UA level is an independ-
ent risk factor for silent brain infarction, 
especially among women (Heo and Lee, 
2010). Taking into account that strokes and 
silent brain infarcts are associated with AF 
(Das et al., 2008), it would be reasonable 
to assume that UA metabolism is involved 
in stroke pathophysiology, at least in part, 
through increased AF risk.
THERAPEUTIC IMPLICATIONS
According to the aforementioned consid-
erations the XO activity rather than UA 
should be the primary target (Doehner 
and Landmesser, 2011) for therapeutic 
interventions. Taking into account that 
UA per se may exert prooxidant effects and 
contribute to atrial remodeling someone 
could argue that lowering UA levels without 
interfering in XO activity may also yield a 
benefit. However, agents that inhibit renal 
reabsorption (uricosuric agents) or pro-
mote degradation of UA failed to show 
improvement in endothelial dysfunction 
or in other clinical variables (Doehner and 
it was demonstrated that after 1 week of 
rapid atrial pacing the detectable NO was 
decreased in the left but not in the right 
atrium, indicating that the oxidative stress 
was enhanced only in the left atrium (Cai 
et al., 2002). It can therefore be speculated 
that the left atrium may be preferentially 
more sensitive to oxidative stress perhaps 
due to lower metabolic reserve or increased 
wall stress (Van Wagoner, 2003).
In patients with right or left heart fail-
ure it has been demonstrated that hyper-
uricemia is related to elevated right or left 
atrial filling pressures (Hoeper et al., 1999). 
Also, UA levels have been correlated with 
more impaired right ventricular systolic 
function and decreased left atrial work in 
patients with heart failure (Chrysohoou 
et al., 2008). It would therefore be specu-
lated that UA metabolism is implicated in 
atrial remodeling given that increased atrial 
filling pressures cause structural and elec-
trophysiological abnormalities (mechano-
electrical phenomenon) that facilitate the 
development and perpetuation of AF. In 
support of this assumption one small study 
showed a correlation between UA levels and 
LA diameter, a conventional marker of atrial 
structural remodeling (Letsas et al., 2010).
Also, there is a possibility that plasma UA 
is primarily a product of XO activity in the 
endothelium, contributing to atrial remod-
eling indirectly, as a result of its impact on 
blood pressure and perhaps by atrial effects 
of UA.
URIC ACID AS A MARKER OF ATRIAL 
FIBRILLATION RISK
An increasing body of evidence evidence 
suggests that UA may represent a marker 
of AF risk. The positive association between 
UA levels and AF has been demonstrated 
in at least seven studies to date (Table 1). 
In a small observational study we showed 
a stepwise increase of UA levels in patients 
with paroxysmal AF and permanent AF 
compared to control subjects while after 
multivariate analysis, UA was an independ-
ent predictor of permanent AF (Letsas et al., 
2010). Also, in a retrospective observational 
study of hospitalized patients over 40 years 
an independent association between high 
serum UA levels and AF (paroxysmal or 
persistent) was evident (Liu et al., 2010). 
In another small observational study we 
demonstrated an independent association 
between increased serum UA levels and 
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upstream strategies represents a subject of 
future research.
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